Phesgo and Tecentriq Performance and Approvals

Q1 2023: Diagnostics Division sales Good base business growth, partially offsetting COVID-19 sales decrease CER=Constant Exchange Rates 2023 2022 Change in % CHFM CHFM CHF CER Diagnostics Division 3,623 5,286 -31 -28 Core Lab 1,928 1,896 2 7 Molecular Lab 593 1,189 -50 -48 Point of Care 397 1,466 -73 -72 Diabetes Care 376 417 -10 -5 Pathology Lab 329 318 3 7 Roche 34

View entire presentation